Akkermansia vs Larazotide
A side-by-side research comparison of Akkermansia and Larazotide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Akkermansia | Larazotide |
|---|---|---|
| Full name | Akkermansia muciniphila (Pasteurized) | Larazotide Acetate (AT-1001) |
| Category | Gut Health | Gut Health |
| Status | Novel food / Supplement | Investigational (Phase 3) |
| Mechanism | Amuc_1100 outer membrane protein activates TLR2 signaling, strengthening gut barrier and improving metabolic endotoxemia. Stimulates mucin production by goblet cells. Enhances GLP-1 secretion and improves insulin signaling. | Acts as a zonulin peptide antagonist, preventing zonulin-mediated disassembly of tight junction proteins (ZO-1, occludin, claudins). Maintains paracellular barrier integrity without systemic absorption. |
| Molecular weight | Whole organism (not applicable) | 1026 Da |
| Half-life | Colonizes mucus layer; effects persist with continued use | Not systemically absorbed (local GI action) |
| Bioavailability | Oral - pasteurized form survives transit; live form colonizes | Minimal systemic absorption (acts locally in GI lumen) |
| Typical dose | 10 billion CFU (pasteurized) or 100mg membrane extract | 0.5-1 mg |
| Frequency | Daily | 3x daily before meals |
| Route | Oral capsule | Oral capsule |
Akkermansia reported benefits
- Improved metabolic markers
- Reduced insulin resistance
- Gut barrier strengthening
- Weight management support
- Reduced systemic inflammation
- Enhanced GLP-1 secretion
Larazotide reported benefits
- Reduced intestinal permeability
- Decreased GI symptoms
- Tight junction restoration
- Reduced systemic inflammation from gut
- Improved gluten tolerance
Related comparisons
Research and educational reference only. Not medical advice.